This post was originally published on this site
(RTTNews) – Vir Biotechnology, Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) announced Tuesday an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial.
The trial is due to begin in the first quarter of 2021.
VIR-7832 is a neutralizing COVID-19 antibody…
Recommended articles
Expensify CEO slams corporate America's response to the Capitol riots: 'Defending the free market does not mean standing by as people destroy it'David Barrett. David BarrettExpensify CEO David Barrett slammed corporate America's response to the attacks on the US Capitol. Barrett told Insider that defending free markets requires first defending...(read more)
Leading Fire Pit Manufacturer, Mr. Bar-B-Q, Announces 2020 Sales, 200% Jump In E-CommerceMELVILLE, N.Y., Jan. 19, 2021 /PRNewswire/ -- Mr. Bar-B-Q, an industry-leading outdoor products company and fire pit manufacturer, today announced 2020 sales results. Overall sales increased 20% with...(read more)
BHP Q2 Iron Ore Production Rises; Lifts FY Iron Ore Production Outlook(RTTNews) - BHP (BHP.AX, BLT.L, BBL, BHP) reported that its second-quarter total iron ore production increased by 3.2 percent to 62.36 million tonnes from last year's 60.40 million tonnes. Total iron...(read more)
Orbia Announces Executive Leadership Appointment<style type="text/css"> <!-- .bwalignc { text-align: center; list-style-position: inside } --> </style> <!-- sh_cad_1 --> Orbia Advance Corporation, S.A.B. de C.V. (B...(read more)
Read the email Expensify's CEO sent to customers on MLK Day outlining the company's plan to fight injustices with a 'highly experimental' crowdsourced campaignExpensifyExpensify will spend an extra $3 million to fight systemic injustices in 2021. CEO David Barrett outlined a "highly experimental" plan to let volunteers and donors choose causes. Expensify wi...(read more)
Bastion Balance Seoul, Korea.